[go: up one dir, main page]

TN2009000510A1 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number
TN2009000510A1
TN2009000510A1 TNP2009000510A TN2009000510A TN2009000510A1 TN 2009000510 A1 TN2009000510 A1 TN 2009000510A1 TN P2009000510 A TNP2009000510 A TN P2009000510A TN 2009000510 A TN2009000510 A TN 2009000510A TN 2009000510 A1 TN2009000510 A1 TN 2009000510A1
Authority
TN
Tunisia
Prior art keywords
nevirapine
extended release
release formulation
pharmaceutical composition
relates
Prior art date
Application number
TNP2009000510A
Other languages
English (en)
Inventor
Michael L Cappolla
Sveltana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2009000510A1 publication Critical patent/TN2009000510A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2009000510A 2007-06-08 2009-12-04 Extended release formulation of nevirapine TN2009000510A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
PCT/US2008/065705 WO2008154234A2 (fr) 2007-06-08 2008-06-04 Formulation à libération prolongée de névirapine

Publications (1)

Publication Number Publication Date
TN2009000510A1 true TN2009000510A1 (en) 2011-03-31

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000510A TN2009000510A1 (en) 2007-06-08 2009-12-04 Extended release formulation of nevirapine

Country Status (28)

Country Link
US (1) US8460704B2 (fr)
EP (1) EP2155169B1 (fr)
JP (1) JP5417662B2 (fr)
KR (1) KR101017862B1 (fr)
CN (1) CN101784263B (fr)
AR (1) AR066924A1 (fr)
AU (1) AU2008262031B2 (fr)
BR (1) BRPI0811732A2 (fr)
CA (1) CA2687491C (fr)
CL (1) CL2008001678A1 (fr)
CO (1) CO6150128A2 (fr)
DK (1) DK2155169T3 (fr)
EA (1) EA018377B1 (fr)
EC (1) ECSP099561A (fr)
ES (1) ES2574836T3 (fr)
HU (1) HUE028598T2 (fr)
IL (1) IL199924A0 (fr)
MA (1) MA31430B1 (fr)
MX (1) MX2009007764A (fr)
NZ (1) NZ578664A (fr)
PE (2) PE20131035A1 (fr)
PL (1) PL2155169T3 (fr)
TN (1) TN2009000510A1 (fr)
TW (1) TWI419716B (fr)
UA (1) UA97971C2 (fr)
UY (1) UY31128A1 (fr)
WO (1) WO2008154234A2 (fr)
ZA (1) ZA200904939B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2008262031B2 (en) 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
EP2714045A1 (fr) 2011-05-30 2014-04-09 Cipla Limited Composition pharmaceutique antirétrovirale
JP6169079B2 (ja) * 2011-08-24 2017-07-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 徐放のための活性剤の製剤
EP2822560A1 (fr) * 2012-03-05 2015-01-14 Cipla Limited Combinaisons pharmaceutiques antirétrovirales comprenant de la lamivudine, du festinavir et de la névirapine
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (fr) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Composition pharmaceutique à libération prolongée de névirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (fr) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines et leur utilisation pour la prevention ou le traitement de l'infection par le hiv
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DK1035834T3 (da) 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
CA2354472C (fr) * 1998-12-17 2009-02-24 Alza Corporation Transformation de capsules de gelatine remplies de fluide en systemes a liberation regulee a l'aide de revetements multiples
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
DE60019334T2 (de) 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (fr) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Utilisation de nevirapine pour traiter ou prevenir des pathologies lipidiques chez des patients presentant une infection par vih resistante a la nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
WO2004043435A2 (fr) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Administration systemique d'agents antiviraux
EP1643946A2 (fr) 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions et procedes de traitement du vih
EP1673072B1 (fr) 2003-10-01 2007-04-04 Lupin Limited Composition pharmaceutique a liberation controlee et procede de preparation de cette composition
JP5661226B2 (ja) 2003-11-13 2015-01-28 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生物浸食性マトリクスコア及び生物浸食性スキンを有する注射可能な持続的放出用の送達用デバイス
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
WO2006114709A1 (fr) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Compositions pharmaceutiques d'antiretroviraux
EA200800162A1 (ru) 2005-06-29 2008-06-30 Панацея Биотек Лтд. Новые фармацевтические композиции с замедленным высвобождением и способы их получения
EP1906937B1 (fr) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Nouvelle composition de comprimé dispersible
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN101309675A (zh) 2005-10-14 2008-11-19 微量技术有限公司 口服剂量组合的药品包装
AU2008262031B2 (en) 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine

Also Published As

Publication number Publication date
NZ578664A (en) 2011-11-25
HUE028598T2 (en) 2016-12-28
KR20100020447A (ko) 2010-02-22
UA97971C2 (ru) 2012-04-10
ECSP099561A (es) 2009-09-29
CL2008001678A1 (es) 2009-09-11
PE20131035A1 (es) 2013-10-01
EA018377B1 (ru) 2013-07-30
CO6150128A2 (es) 2010-04-20
WO2008154234A3 (fr) 2010-01-21
AR066924A1 (es) 2009-09-23
EP2155169A2 (fr) 2010-02-24
AU2008262031B2 (en) 2011-08-25
PL2155169T3 (pl) 2016-09-30
WO2008154234A9 (fr) 2009-11-26
WO2008154234A2 (fr) 2008-12-18
MX2009007764A (es) 2009-09-10
HK1145806A1 (en) 2011-05-06
UY31128A1 (es) 2009-01-30
CA2687491C (fr) 2011-09-20
US20100278918A1 (en) 2010-11-04
MA31430B1 (fr) 2010-06-01
PE20090371A1 (es) 2009-04-24
ES2574836T3 (es) 2016-06-22
EA200900958A1 (ru) 2010-04-30
EP2155169B1 (fr) 2016-03-23
KR101017862B1 (ko) 2011-03-04
CA2687491A1 (fr) 2008-12-18
BRPI0811732A2 (pt) 2014-11-18
CN101784263A (zh) 2010-07-21
CN101784263B (zh) 2012-11-07
JP5417662B2 (ja) 2014-02-19
US8460704B2 (en) 2013-06-11
AU2008262031A1 (en) 2008-12-18
IL199924A0 (en) 2010-04-15
TWI419716B (zh) 2013-12-21
TW200916127A (en) 2009-04-16
JP2010520891A (ja) 2010-06-17
DK2155169T3 (en) 2016-06-13
ZA200904939B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
MY153915A (en) Organic compounds
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
SMT201700189T1 (it) Composizioni farmaceutiche di albiglutide
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
EP2129672A4 (fr) Dérivés ester et carbamate d'azaadamantane et leurs procédés d'utilisation
IN2012DN03404A (fr)
MX2010008852A (es) Formulaciones de flibanserina.
ZA201102652B (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
EP2296687A4 (fr) Compositions pharmaceutiques de conjugués somatostatine-dopamine
MY165088A (en) Pharmaceutical compositions comprising alisporivir
IL212171A (en) 1-Phenylpyrol compounds, pharmaceuticals containing them and their use
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
AP2012006119A0 (en) Pharmaceutical composition of isoniazid.
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.